Arizona Teacher Named to Curriculum Associates' 2025 Class of Extraordinary Educators™
PHOENIX, June 2, 2025 /PRNewswire/ -- Curriculum Associates has named Maggie Linneer of Tumbleweed School in Phoenix, Arizona to its 2025 class of Extraordinary Educators, an annual program that celebrates and connects teachers from across the country who go above and beyond for their students in Grades K–8. Selected from hundreds of nominations, Linneer is part of a select group of 29 educators who exhibit best-in-class use of i-Ready, i-Ready Classroom Mathematics, and/or Ready®. Linneer has also promoted growth and achievement through interim assessments, pioneered innovative engagement strategies, and stretched the expectations and achievements of her students.
"My favorite thing about being an educator is getting to know each of my students individually, including their strengths, needs, and social-emotional development," says Linneer. "i-Ready gives me the tailored data I need to ensure I am building strong relationships with my students and providing a supportive and collaborative environment."
This year's class of Extraordinary Educators includes a diverse range of backgrounds and roles—from classroom teachers to specialists and gifted support teachers. Each educator's application was reviewed by an internal selection committee composed of Curriculum Associates employees with various roles across the company and finalized by an advisory board that included Curriculum Associates and Extraordinary Educators alumni.
"The impact these teachers make creates ripple effects in their communities and across the country," said Kelly Sia, CEO of Curriculum Associates. "We are delighted to celebrate these remarkable educators and the transformative work they do to ensure better students outcomes. Our Extraordinary Educators, selected from hundreds of nominations and submissions, embody our mission of impact in the classroom and work to unlock the potential of every student."
This class of Extraordinary Educators will enjoy continued access to a network of their distinguished peers from across the country to collaborate, connect, and explore new and unique ways to prepare the next generation of learners. They will also receive access to professional learning opportunities, including an invitation to participate and present at the annual Extraordinary Educators Leadership Summit and other professional learning events.
About Curriculum AssociatesFounded in 1969, Curriculum Associates is a mission-driven education company committed to grade-level success for every learner. We support more than 14 million students and one million teachers across the U.S. with our award-winning service and evidence-based programs including i-Ready®, Magnetic®, and BRIGANCE®. Learn more at www.curriculumassociates.com.
Media contact: press@cainc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/arizona-teacher-named-to-curriculum-associates-2025-class-of-extraordinary-educators-302471000.html
SOURCE Curriculum Associates, LLC
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Industry Leader in Lyophilization, Dr. Serguei Tchessalov, Partners with BioTechnique ® to Enhance Customer Capabilities
YORK, Pa.--(BUSINESS WIRE)--BioTechnique ® LLC ('BioTechnique' or the 'Company') proudly welcomes Dr. Serguei Tchessalov, a globally recognized subject matter expert in lyophilization, whose decades of experience in formulation development, process design, and scale-up bring invaluable insight to clients navigating complex biologic and vaccine manufacturing. With over 40 years of experience spanning both Russia and the United States, Dr. Tchessalov brings deep expertise in the formulation and freeze-drying of bacterial, viral, and mRNA-based vaccines, proteins, and other complex biologics. He holds a Ph.D. in Biotechnology Engineering from the Institute of Applied Biochemistry in Moscow, where his research focused on novel formulation and process control methods for lyophilization. After completing postdoctoral training with Professor Michael Pikal at the University of Connecticut, he went on to hold roles at Immunex, Wyeth, and Pfizer, contributing to industry-leading development efforts. Dr. Tchessalov is the founder of SN Lyophilization, a consulting firm dedicated to freeze-drying and parenteral drug product processing. With over 30 scientific publications to his name, his current work focuses on lyophilization scale-up and transfer, as well as processing operations including filtration, filling, freezing, and thawing. His partnership with BioTechnique strengthens the company's ability to support clients with practical, science-driven solutions across the entire drug product lifecycle. BioTechnique ® 's Lyophilization Capabilities At BioTechnique ®, lyophilization is a core competency backed by robust infrastructure and scientific expertise. Our state-of-the-art, aseptic manufacturing facility is equipped to support both clinical and commercial-scale freeze-drying of biologics, including monoclonal antibodies, peptides, vaccines, and other sensitive drug products. We offer flexible lyophilizer configurations, precise cycle development, and seamless tech transfer—all executed under strict cGMP conditions. Whether clients require formulation support, cycle optimization, troubleshooting, or full-process development, BioTechnique provides tailored solutions that prioritize product stability, yield, and regulatory compliance. With Dr. Tchessalov's guidance, our clients gain not only access to advanced modeling tools and industry best practices, but also the strategic insight needed to successfully navigate the complexities of lyophilization from early development through commercialization. For more information on BioTechnique's capabilities, visit
Yahoo
3 hours ago
- Yahoo
Mission Wealth Named No. 3429 on the 2025 Inc. 5000 List of America's Fastest-Growing Private Companies
Nationally recognized wealth management firm ranks No. 3429 in 2025, continuing a decade-long track record of growth and excellence. SANTA BARBARA, Calif., Aug. 12, 2025 /PRNewswire/ -- Inc ., the leading media brand for entrepreneurs and business leaders, today announced that Mission Wealth has ranked No. 3429 on its annual Inc. 5000 list , a prestigious ranking of the fastest-growing private companies in America. This marks Mission Wealth's ninth appearance on the list, underscoring the firm's sustained growth, client-first approach, and dedication to innovation in wealth management. The Inc . 5000 list offers a data-driven snapshot of the most successful companies in the economy's most dynamic segment—independent, entrepreneurial businesses. The nationally accredited registered investment advisory firm's 3-year growth rate topped 114%. "Being recognized on the Inc . 5000 for the ninth time is a testament to the dedication of our team and the trust our clients place in us," said Matthew Adams , CEO and Managing Partner of the nationally recognized Mission Wealth. "Our growth has been fueled by a clear vision: to empower clients to achieve true wealth by aligning their financial strategies with their life goals. We're proud to have navigated changing markets while maintaining our unwavering commitment to personalized service and impactful advice." This year's honorees demonstrated exceptional growth while navigating economic uncertainty, inflationary pressures, and a shifting labor market. Mission Wealth's consistent presence on the list reflects its ability to adapt, innovate, and deliver value to its growing client base nationwide. Mission Wealth's Previous Inc. Honors Inc. 5000: No. 3860 (2024), No. 3746 (2023), No. 3858 (2022), No. 4260 (2021), No. 4450 (2018), No. 3607 (2017), No. 3094 (2016), No. 2907 (2015) Inc. Best Workplaces: 2025, 2024, 2023, 2022, 2021, 2020, 2018 Inc. Best in Busines s : 2022 (Financial Services) Inc. Regionals Pacific: No. 151 (2023) Please view all Mission Wealth awards and honors here . For the complete list, company profiles, and a searchable database by industry and location, visit: . "Making the Inc . 5000 is always a remarkable achievement, but earning a spot this year speaks volumes about a company's tenacity and clarity of vision," says Mike Hofman, editor-in-chief of Inc . "These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn't just weather the storm—they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy." About Inc. and MethodologyInc . is the leading media brand and playbook for entrepreneurs and business leaders shaping our future. Companies on the 2025 Inc . 5000 are ranked according to percentage revenue growth from 2021 to 2024. To qualify, companies must have been founded and generating revenue by March 31, 2021. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2024. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2021 is $100,000; the minimum for 2024 is $2 million. An administrative fee of $295 was paid to apply. As always, Inc. reserves the right to decline applicants for subjective reasons. For more information, visit . About Mission WealthSince 2000, Mission Wealth has been a nationally recognized Registered Investment Advisor (RIA) dedicated to serving over 4,225 valued clients and families and managing assets exceeding $12.2 billion across the United States. For comprehensive information about Mission Wealth's core values and services, please visit or contact us at 805-516-5187 for a complimentary financial planning consultation. Follow Mission Wealth's Growth: LinkedIn | Instagram | YouTube MISSION WEALTH IS A REGISTERED INVESTMENT ADVISOR. ALL RIGHTS RESERVED. 00780022 08/25 View original content to download multimedia: SOURCE Mission Wealth Management, LP Inicia sesión para acceder a tu cartera de valores
Business Wire
3 hours ago
- Business Wire
TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the 'Company'), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended June 30, 2025, and provides an operational update. 'TriSalus continued to deliver strong commercial momentum in the second quarter, underscoring the growing clinical adoption of our TriNav ® product suite and proprietary PEDD ® platform across a broad range of solid tumor indications,' said Mary Szela, President and CEO of TriSalus. 'We are pleased to reaffirm our full-year revenue growth guidance of 50%, reflecting increasing market penetration within liver-directed therapies. We will continue to invest in clinical data to extend the benefits of our PEDD technology platform to new embolization applications. With a strategic shift toward partnering development of Nelitolimod and an expanded focus on liver-directed therapies and new applications, we are energized by the opportunity to bring our PEDD technology to a wider range of patients which will not only support improved clinical outcomes but also drive deeper physician engagement and commercial momentum, fueling our long-term vision.' Second Quarter 2025 Highlights Generated $11.2 million in net sales, a 52% increase year-over-year, and sequential growth of 22% over the first quarter 2025. Continued strong commercial momentum with expanded use of TriNav ® in liver embolization and continued to further develop new applications in new clinical settings focused on the interventional radiology specialty. Expanded product portfolio with the successful launch of TriNav ® FLX, the latest advancement in Pressure-Enabled Drug Delivery (PEDD). Designed with a more flexible distal tip, TriNav FLX enhances navigability through tortuous vessels—providing an effective solution for physicians previously limited by anatomical barriers to PEDD adoption. Early market response has been strong, with sales surpassing internal projections. Subsequent to the second quarter, the Company simplified its capital structure through the successful completion of an exchange offering of previously issued Series A Preferred stock. Second Quarter 2025 Financial Highlights Revenue, all from the sale of the TriNav system, was $11.2 million for the three months ended June 30, 2025, an increase of 52% compared to the same period in 2024 and 22% sequential growth. Revenue growth was driven primarily by increased selling resources and increased market share. Gross margins were 84% in the second quarter, compared to 88% in the same period of 2024. The year-over-year decline was primarily driven by lower manufacturing efficiency associated with newly launched products, a dynamic we expect to improve as production scales and processes mature over the course of the year. Research and Development (R&D) expenses were approximately $3.9 million, compared to $4.7 million for the same quarter of the prior year. The decline in R&D costs is primarily a result of a decline in clinical trial costs relating to Nelitolimod. Sales and Marketing (S&M) expenses were approximately $7.2 million in the second quarter, compared to $6.0 million for the same quarter of the prior year. The year-over-year increase reflects continued investment in the expansion of our commercial organization. General & Administrative (G&A) expenses were approximately $5.7 million, compared to $4.0 million for the same quarter of the prior year. G&A costs include non-cash stock-based compensation of $1.2 million and $0.7 million, respectively, for the same periods. The increase in G&A costs is primarily a result of professional services related to legal services and audit. Operating losses were $7.3 million, compared to Operating losses of $8.2 million for the same period in 2024. Current reductions in operating losses are due to reduced research and development expenses associated with the ramp-down of Nelitolimod clinical trial spending. Net loss attributable to common stockholders was $9.0 million, compared to $5.1 million for the same period in 2024, primarily due to non-cash adjustments to the fair value of our contingent earnout liability. The basic and diluted loss per share was $0.27, compared to $0.21 for the same period in 2024. As of June 30, 2025, cash and cash equivalents totaled $26.5 million providing sufficient runway to reach positive adjusted EBITDA in the first half of 2026. The non-GAAP measure of adjusted EBITDA is reconciled in the table below as the Company believes it is an important measure of performance. Adjusted EBITDA losses were $5.3 million, compared to losses of $6.7 million for the same period in 2024. Currently, reductions in adjusted EBITDA losses are due to increased sales, reduced research and development expenses and increased stock compensation in 2025. Conference Call The Company will host a conference call and webcast today at 4:30 PM eastern time to discuss its financial results for the quarter ended June 30, 2025. Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin. The event will also be webcast live on the investor relations section of TriSalus' website. A replay will also be available on the website following the event. About TriSalus Life Sciences TriSalus Life Sciences ® is an oncology focused medical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company's platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company's two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD) approach to deliver a range of therapeutics: the TriNav ® Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. The PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolimod, the Company's investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that nelitolimod delivered via the PEDD technology may have favorable immune effects within the liver and systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by the PEDD technology are commonly present as well. The Company is in the final stages of data completion for a number of phase 1 clinical trials and will begin exploring partnership opportunities for development. Forward Looking Statements Statements made in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the benefits and potential benefits of the Company's PEDD drug delivery technology, TriNav ® system and nelitolimod investigational immunotherapy, and the Company's ability to execute on its strategy. Risks that could cause actual results to differ from those expressed in these forward-looking statements include risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates, including that future clinical results may not be consistent with patient data generated during the Company's clinical trials, the cost and timing of all development activities and clinical trials, unexpected safety and efficacy data observed during clinical studies, the risks associated with the credit facility, including the Company's ability to remain in compliance with all its obligations thereunder to avoid an event of default, the risk that the Company will continue to raise capital through the issuance and sale of its equity securities to fund its operations, the risk that the Company will not be able to achieve the applicable revenue requirements to access additional financing under the credit facility, the risk that the Company will not become profitable on its expected timeline, if at all, the risk that the reported financial results will differ from the estimates provided in this press release, changes in expected or existing competition or market conditions, changes in the regulatory environment, unexpected litigation or other disputes, unexpected expensed costs, made in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the benefits and potential benefits of the Company's PEDD drug delivery technology, TriNav ® system and nelitolimod investigational immunotherapy, and the Company's ability to execute on its strategy. Risks that could cause actual results to differ from those expressed in these forward-looking statements include risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates, including that future clinical results may not be consistent with patient data generated during the Company's clinical trials, the cost and timing of all development activities and clinical trials, unexpected safety and efficacy data observed during clinical studies, the risks associated with the credit facility, including the Company's ability to remain in compliance with all its obligations thereunder to avoid an event of default, the risk that the Company will continue to raise capital through the issuance and sale of its equity securities to fund its operations, the risk that the Company will not be able to achieve the applicable revenue requirements to access additional financing under the credit facility, the risk that the Company will not become profitable on its expected timeline, if at all, the risk that the reported financial results will differ from the estimates provided in this press release, changes in expected or existing competition or market conditions, changes in the regulatory environment, unexpected litigation or other disputes, unexpected expensed costs, and other risks described in the Company's filings with the Securities and Exchange Commission under the heading 'Risk Factors.' All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made except as required by law. TRISALUS LIFE SCIENCES, INC. Condensed Consolidated Balance Sheets (unaudited, in thousands) December 31, 2024 Assets Current assets: Cash and cash equivalents $ 26,490 $ 8,525 Accounts receivable, net 5,571 5,087 Inventory, net 3,807 4,048 Prepaid expenses 2,216 3,009 Total current assets 38,084 20,669 Property and equipment, net 1,711 1,669 Right-of-use assets 1,103 1,210 Other assets 419 423 Total assets $ 41,317 $ 23,971 Liabilities and Stockholders' Deficit Current liabilities: Trade payables $ 1,902 $ 2,274 Accrued liabilities 7,078 7,355 Short-term lease liabilities 123 216 Other current liabilities 221 383 Total current liabilities 9,324 10,228 Long-term debt, net of unamortized discount and debt issuance costs 32,274 22,084 Revenue base redemption liability 358 507 Long-term lease liabilities 1,265 1,329 Contingent earnout liability 7,522 7,401 Warrant and SEPA liabilities 9,997 8,316 Total liabilities 60,740 49,865 Commitments and contingencies Stockholders' deficit: Preferred Stock, Convertible Series A, $0.0001 par value per share, $10.00 liquidation value per share. Authorized 10,000,000 shares at June 30, 2025 and December 31, 2024, respectively; issued and outstanding, 3,594,002 and 3,985,002 shares at June 30, 2025, and December 31, 2024, respectively. — — Common stock, $0.0001 par value per share. Authorized 400,000,000 shares at June 30, 2025 and December 31, 2024, respectively; issued and outstanding, 37,983,259 and 31,279,264 shares at June 30, 2025, and December 31, 2024, respectively. 3 3 Additional paid-in capital 278,786 253,652 Accumulated deficit (298,212 ) (279,549 ) Total stockholders' deficit (19,423 ) (25,894 ) Total liabilities and stockholders' deficit $ 41,317 $ 23,971 Expand Non-GAAP Financial Measure To supplement the financial results presented in accordance with GAAP, TriSalus has also included in this press release non-GAAP adjusted EBITDA, which excludes from net loss, income tax expense, interest expense, interest income, change in fair value of SEPA, warrant and revenue-base redemption liabilities, change in fair value of contingent earn out liability, stock-based compensation expense and depreciation. These non-GAAP financial measures are not prepared in accordance with GAAP, do not serve as an alternative to GAAP and may be calculated differently than similar non-GAAP financial information disclosed by other companies. TriSalus encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations set forth below, to more fully understand TriSalus' business. TriSalus believes that the presentation of these non-GAAP financial measures provides useful supplemental information to, and facilitates additional analysis by, investors. In particular, TriSalus believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare TriSalus' results from period to period, and to identify operating trends in TriSalus' business.
